Purpose Of Review: The effects of statin loading before, during or after vascular interventions on cardiovascular and renal outcomes are discussed. Furthermore, the selection of optimal statin type and dose, according to current evidence or guidelines, is considered. The importance of treating statin intolerance and avoiding statin discontinuation is also discussed.
Recent Findings: Statin loading has been shown to beneficially affect cardiovascular outcomes, total mortality and/or contrast-induced acute kidney injury, in patients undergoing vascular procedures such as percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), carotid endarterectomy (CEA), carotid artery stenting, endovascular aneurysm repair, open abdominal aortic aneurysms (AAA) repair and lower extremities vascular interventions. High-dose statin pretreatment is recommended for PCI and CABG according to current guidelines. Statin discontinuation should be avoided during acute cardiovascular events and vascular interventions; adequate measures should be implemented to overcome statin intolerance.
Summary: Statin loading is an important clinical issue in patients with cardiac and noncardiac vascular diseases, including carotid artery disease, peripheral artery disease and AAA, undergoing vascular interventions. Cardiologists and vascular surgeons should be aware of current evidence and implement guidelines in relation to statin loading, discontinuation and intolerance.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/HCO.0000000000000519 | DOI Listing |
Objective: Excess cholesterol loading on arterial macrophages is linked to foam cell formation, atherosclerosis and cardiovascular risk in rheumatoid arthritis (RA). However, the effect of changes in cholesterol loading on coronary plaque trajectory and the impact of RA therapies on this relationship are unknown. We investigated the association between variations in cholesterol loading capacity (CLC) over time and atherosclerosis progression.
View Article and Find Full Text PDFCureus
November 2024
Interventional Cardiology Department, Lady Reading Hospital, Peshawar, PAK.
Background: Primary percutaneous coronary intervention (PCI) is crucial in managing acute ST-segment elevation myocardial infarction (STEMI), emphasizing the importance of optimal myocardial reperfusion.
Objective: The goal of this research was to determine how loading doses of rosuvastatin and atorvastatin affected the flow rate of thrombolysis in myocardial infarction (TIMI) immediately post-perfusion thrombolysis in patients undergoing primary PCI.
Methodology: This prospective, comparative study was carried out over a one-year period (January 2023 to December 2023) in Pakistan.
Int J Pharm
January 2025
Faculty of Pharmacy, Alamein International University, Alamein 51718, Matrouh, Egypt. Electronic address:
This study aimed at preparing sustained release rosuvastatin (Ru) calcium carbonate (CC) co-precipitate nano-formulation for local intra-osseous application in osteoporotic rats. Nano-formulations were prepared by the co-precipitation method using different concentrations of polyvinyl alcohol (PVA) (0.2, 0.
View Article and Find Full Text PDFInt J Biol Macromol
December 2024
Cellulose & Composites Research Group, Department of Materials Science and Metallurgical Engineering, Indian Institute of Technology, Hyderabad, Kandi, 502285 Sangareddy, Telangana, India. Electronic address:
Bacterial cellulose (BC) stands out as a promising candidate for novel drug delivery systems due to its micro-mesoporous nanofibrous interconnected structure. However, its performance is limited by the burst release of hydrophilic drugs and lower incorporation of the less water-soluble or insoluble drugs. In this study, we explored its potential as a drug carrier for two distinct types of drugs: Diclofenac sodium and Simvastatin, representing water-soluble and water insoluble compounds, respectively.
View Article and Find Full Text PDFInt J Nanomedicine
November 2024
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, 4410240, Egypt.
Introduction: Atorvastatin (ATV), a medication used to reduce cholesterol levels, possesses properties that can counteract the damaging effects of free radicals and reduce inflammation. However, the administration of ATV orally is associated with low systemic bioavailability due to its limited capacity to dissolve in water and significant first-pass effect. This study aimed to assess the appropriateness of employing nano-vesicles for transdermal administration of ATV in order to enhance its anti-inflammatory effects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!